Abstract: The present invention concerns a polynucleotide construct encoding a mini-receptor of SORLA. The present invention further concerns a vector, a cell and/or a composition comprising said polynucleotide construct. The present invention further concerns a polypeptide representing a mini-receptor of SORLA. The present invention further concerns said vector, said cell and/or said composition comprising said poly nucleotide construct, for use in medicine. The present invention further concerns said vector, said cell and/or said composition comprising said polynucleotide construct, for use in treatment, prevention and/or alleviation of Alzheimer's Disease or a disease or disorder associated with Alzheimer's Disease. The present invention further concerns a method of treating Alzheimer's Disease or a disease or disorder associated with Alzheimer's Disease. The present invention further concerns a method of increasing sAPP? in a cell.

Abstract: The present disclosure concerns antisense oligonucleotide (ASO) capable of binding to a target site on the pre-mRNA of SORL1. The present disclosure further concerns a composition comprising said ASO. The present disclosure further concerns an ASO for use in medicine. The present disclosure further concerns an ASO for use in the prevention, treatment and/or alleviation of Alzheimer's Disease (AD), or a disease or disorder associated with Alzheimer's Disease. The present disclosure further concerns a method for mediating exon skipping in SORL1 transcripts, a method of determining the efficiency of ASO mediated SORL1 exon skipping, a method for testing if a patient identified with a SORL1 mutation will benefit from treatment with an ASO mediating exon skipping, and a method of producing an ASO.

Abstract: The present invention relates to a sorLA-based drug screening platform for use in screening compound libraries for an effect on endosomal activity.

Abstract: The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps10p-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and/or nociception in an individual.

Abstract: The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps1 Op-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and/or nociception in an individual.

Abstract: The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps1 Op-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and/or nociception in an individual.

Abstract: The present invention provides agents for inhibiting binding of a pro-neurotrophin to a Vps10p-domain receptor, in particular the binding of a pro-NGF or a pro-BDNF to a Sortilin receptor. The invention thus provides agents for the manufacture of a medicament, for treating and/or preventing disease or disorders such as but not limited to neurological, neuropsychiatric and ocular diseases, disorders, and degeneration as well as obesity, diabetes, pain and/or nociception in an individual.